Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
July 21 2022 - 1:00PM
Athenex (NASDAQ: ATNX), a global biopharmaceutical
company dedicated to the discovery, development, and
commercialization of novel therapies for the treatment of cancer
and related conditions, today announced that the Company will
provide a corporate and financial update for the second quarter
2022 on Thursday, July 28, 2022, before the market opens. Athenex’s
management team will host a conference call and live audio webcast
at 8:00 a.m. Eastern Time.
To participate in the call, dial either the domestic or
international number fifteen minutes before the conference call
begins:
Domestic: (855) 327-6837
International: (631) 891-4304
Passcode: 10019801
The live conference call and replay can also be accessed via
audio webcast here and on the Investor Relations section of the
Company’s website under “Events and Presentations”, located at
http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a
global clinical-stage biopharmaceutical company dedicated to
becoming a leader in the discovery, development, and
commercialization of next generation cell therapy drugs for the
treatment of cancer. In pursuit of this mission,
Athenex leverages years of experience in research and
development, clinical trials, regulatory standards, and
manufacturing. The Company’s current clinical pipeline is derived
mainly from the following core technologies: (1) Cell therapy,
based on NKT cells and (2) Orascovery, based on a P-glycoprotein
inhibitor. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active, accessible
and tolerable treatments. For more information, please
visit www.athenex.com.
Athenex Contacts
Investor Relations
Daniel Lang, MDAthenex, Inc.E-mail: danlang@athenex.com
Caileigh DoughertyAthenex, Inc.E-mail:
cdougherty@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024